BeOne Medicines Ltd. (ONC) Stock Analysis
Recovery setup
Conditional: analysts disagree (1.5× target spread) — below strong-conviction threshold. Size accordingly.
Healthcare · Biotechnology
Buy at $315.55 (limit $312.12). A.R:R 2.6:1 at $315.55 — the engine's gate value (upside to target $370.14 vs. downside set by the wider of 2×ATR or distance-to-support, clipped 5-15%). You'd stand to gain ~$55 per share to target. Key risk: Concentration risk — Product: BRUKINSA.
BeOne Medicines is a global oncology company that generated approximately $5.3 billion in total revenue in 2025, a 40.2% increase year-over-year. BRUKINSA, its BTK inhibitor approved in over 75 markets, became the global market leader across B-cell malignancies and generated... Read more
Buy at $315.55 (limit $312.12). A.R:R 2.6:1 at $315.55 — the engine's gate value (upside to target $370.14 vs. downside set by the wider of 2×ATR or distance-to-support, clipped 5-15%). You'd stand to gain ~$55 per share to target. Key risk: Concentration risk — Product: BRUKINSA. Chart setup: Death cross but MACD improving, RSI 45. Growth is outpacing valuation and the chart agrees (PEG 0.00, quality 7.5/10, growth 10.0/10). Score 6.8/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.70, news boost analyst cluster(3), earnings proximity 86d clear, semi cycle peak clear). Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductBRUKINSA10-K Item 1A: 'BRUKINSA generated $3.9 billion in sales in 2025'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 ceiling hit
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Buy at $315.55 (limit $312.12). A.R:R 2.6:1 at $315.55 — the engine's gate value (upside to target $370.14 vs. downside set by the wider of 2×ATR or distance-to-support, clipped 5-15%). You'd stand to gain ~$55 per share to target. Key risk: Concentration risk — Product: BRUKINSA. Chart setup: Death cross but MACD improving, RSI 45. Growth is outpacing valuation and the chart agrees (PEG 0.00, quality 7.5/10, growth 10.0/10). Target $370.14 (+17.3%), stop $296.26 (−6.5%), A.R:R 2.6:1. Score 6.8/10, moderate confidence.
Take-profit target: $370.14 (+18.6% upside). Target $370.14 (+17.3%), stop $296.26 (−6.5%), A.R:R 2.6:1. Stop-loss: $296.26.
Concentration risk — Product: BRUKINSA.
BeOne Medicines Ltd. trades at a P/E of 70.5 (forward 34.5). TrendMatrix value score: 5.7/10. Verdict: Strong Buy.
15 analysts cover ONC with a consensus score of 4.1/5. Average price target: $411.
What does BeOne Medicines Ltd. do?BeOne Medicines is a global oncology company that generated approximately $5.3 billion in total revenue in 2025, a...
BeOne Medicines is a global oncology company that generated approximately $5.3 billion in total revenue in 2025, a 40.2% increase year-over-year. BRUKINSA, its BTK inhibitor approved in over 75 markets, became the global market leader across B-cell malignancies and generated $3.9 billion in 2025 sales. The company reported net income of $286.9 million and positive free cash flow of $941.7 million.